KRAS mutations are found in 40% of metastatic colorectal cancer, whilst BRAF mutations are only seen in 10–15% of metastatic disease [14], suggesting that the adenoma-carcinoma pathway has a greater metastatic potential. This evidence concerns the gene KRAS and carcinoma.